Inclusion Criteria:
- Male or female, 18 years of age or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically or cytologically confirmed, Stage IV non-squamous NSCLC
- No prior treatment for Stage IV non-squamous NSCLC. Participants with a sensitizing
mutation in the epidermal growth factor receptor (EGFR) gene or with an anaplastic
lymphoma kinase (ALK) fusion oncogene are excluded.
- Participants who have received prior neo-adjuvant, adjuvant chemotherapy, or
chemoradiotherapy with curative intent for non-metastatic disease must have
experienced a treatment-free interval of at least 6 months from randomization since
the last chemotherapy or completion of chemoradiotherapy
- Known programmed death-ligand 1 (PD-L1) tumor status as determined by an
immunohistochemistry (IHC) assay performed by a central laboratory on previously
obtained archival tumor tissue or tissue obtained from a biopsy at screening
- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors
Version 1.1 (RECIST v1.1)
- Adequate hematologic and end organ function
- For women of childbearing potential: agreement to remain abstinent or use
contraceptive methods that result in a failure rate of less than (<) 1 percent (%)
per year during the treatment period and for at least 90 days after the last dose of
study treatment
- For men: agreement to remain abstinent or use contraceptive measures and agreement to
refrain from donating sperm
Exclusion Criteria:
Cancer-Specific Exclusions
- Active or untreated central nervous system (CNS) metastases as determined by computed
tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and
prior radiographic assessments
- Spinal cord compression not definitively treated with surgery and/or radiation or
previously diagnosed and treated spinal cord compression without evidence that
disease has been clinically stable for >= 2 weeks prior to randomization
- Leptomeningeal disease
- Uncontrolled tumor-related pain
- Uncontrolled or symptomatic hypercalcemia (greater than [>] 1.5 millimole/Liter
ionized calcium or calcium > 12 milligram/deciliter or corrected serum calcium >upper
limit of normal)
- Malignancies other than NSCLC within 5 years prior to randomization
- Known tumor PD-L1 expression status from other clinical studies (e.g., participants
whose PD-L1 expression status was determined during screening for entry into a study
with anti-PD-1 or anti-PD L1 antibodies but were not eligible are excluded)
General Medical Exclusions:
- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins
- History of certain autoimmune disease
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
- Severe infections within 4 weeks prior to randomization
- Significant cardiovascular disease, such as New York Heart Association cardiac
disease (Class II or greater), myocardial infarction within 3 months prior to
randomization, unstable arrhythmias, or unstable angina
Exclusion Criteria Related to Medications and Chemotherapy:
- Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within
3 weeks prior to initiation of study treatment
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies,
anti-PD-1, and anti-PD-L1 therapeutic antibodies
- Treatment with systemic immunostimulatory agents within 4 weeks prior to
randomization
- Treatment with systemic immunosuppressive medications
Exclusion Criteria Related to Chemotherapy:
- History of allergic reactions to cisplatin, carboplatin, or other platinum-containing
compounds
- Participants with hearing impairment (cisplatin)
- Grade >= 2 peripheral neuropathy as defined by National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria (cisplatin)
- Creatinine clearance (CRCL) =< 60 milliliter (mL)/minute (min) for cisplatin or < 45
mL/min for carboplatin
Minimum Eligible Age: 18 Years
Maximum Eligible Age: N/A
Eligible Gender: Both
Overall Survival Time
Percentage of Participants with an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1
Duration of Response as Determined by the Investigator Using RECIST v1.1
Time to Response as Determined by the Investigator According to RECIST v1.1
Progression Free Survival Time as Determined by the Independent Review Facility Using RECIST V1.1
Percentage of Participants Who Were Alive after One and Two Years\n
Time to Deterioration in Patient-Reported Lung Cancer Symptoms Using European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) and Lung Cancer Module (EORTC QLQ-LC13) Symptom Subscales
Time to Deterioration in Patient-Reported Lung Cancer Symptoms Using the Symptoms in Lung Cancer (SILC) Scale Symptom Score\n
Maximum Observed Serum Atezolizumab Concentration (Cmax) After Infusion (Arm A)
Minimum Observed Serum Atezolizumab Concentration (Cmin) Prior to Infusion (Arm A)\n
Plasma Concentrations for Carboplatin or Cisplatin (Arm A) Cmax
Plasma Concentrations for Pemetrexed (Arm A)